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ABSTRACT
The first successful lung transplantation (LTx) was per-
formed in 1983. Since then, more than 10 000 LTx
have been performed in the world, with approximately
1000 new cases each year in recent years. Lung trans-
plantation is established as the ultimate treatment for
end-stage pulmonary diseases. Clinical application of
LTx was delayed in Japan because of difficulty in
acceptance of brain death. The Japanese Brain Death
Act (JBDA) for organ transplantation was enforced in
October 1997. Now, LTx from a brain-dead cadaver
donor (BDCD) becomes a clinical option for end-stage
lung diseases in this country. Four LTx centers were
selected and the registration of candidates for LTx
started in August 1998. In total, up until May 2001, 51
patients had been registered on a waiting list. Patients’
diseases for LTx in Japan are different from those 
in the US and Europe. So far, primary pulmonary
hypertension (PPH; n = 23), idiopathic pulmonary
fibrosis/interstitial pneumonia (IPF/IIP; n = 8), lymph-
angioleiomyomatosis (LAM; n = 7) and bronchiectasis
(BE; n = 6) are the major indications for LTx in Japan.
Fourteen patients (27%) have died while waiting for LTx
and only eight patients (14%) have received lung allo-
grafts. The BDCD are quite precious and, thus far, only
13 donors have become available after enforcement
of the JBDA. Although the average utilization of BDCD
for LTx was reported to be only 10–20%, positive utility
of marginal donors in Japan has led to a higher rate
(five of 13; 36%). Six LTx were performed from five
BDCD. These included five single LTx (LAM n = 3;
IPF/IIP n = 2) and one bilateral LTx (PPH n = 1).
Because there are few BDCD in Japan, living-donor
lobar LTx (LDLTx) is thought to be the optimal choice
for selected patients. Eight LDLTx (BE n = 2; bronchi-
olitis obliterans n = 2; IPF/IIP n = 2; LAM n = 1; and
PPH n = 1) have been performed. All recipients who
received a LTx in Japan are alive and doing well at
present.
Key words: brain-dead cadaver donor, bronchi-
ectasis, idiopathic pulmonary fibrosis, living-donor
lobar lung transplantation, lung transplantation,
lymphangioleiomyomatosis, primary pulmonary hyper-
tension.
INTRODUCTION
After the first successful lung transplantation (LTx) in
1983,1 more than 10 000 LTx have been performed in
the world, with approximately 1000 new cases each year
in recent years.2 Lung transplantation is established as the
ultimate treatment for end-stage pulmonary diseases in
developed countries, except Japan. Clinical application
of LTx was delayed in Japan until the Japanese Brain
Death Act (JBDA) for organ transplantation was enforced
in October 1997. Major indications for LTx in Japan are
quite different from those in Western countries. Six LTx
from brain-dead cadaver donors (BDCDs) have been
performed in Japan and LTx becomes a clinical option for
end-stage lung diseases in our country. Because BDCDs
are quite precious, LTx from living donors is thought to be
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an alternative choice for selected patients, as well as
renal or liver transplantation, in Japan. The present
review analyzes the current status and future trends of LTx
in Japan.
CURRENT STATUS OF LTX IN JAPAN
Indication for LTx and the transplant window
in Japan
Clinical organ transplantation from BDCD was not
accepted for a long time in Japan. After the submission of
a report from the National Brain Death Investigative
Committee in 1992, the JBDA for organ transplantation
was enforced in October 1997. Since then, organ trans-
plantation from BDCD has become a real clinical option
in this country. Four lung transplant centers were selected
in April 1998 and registration of candidates for LTx
started in August 1998.3 The indicated lung diseases for
LTx in Japan are limited to chronic advanced lung disor-
ders for which no further medical or surgical therapies
are available. Japanese criteria for LTx include a limita-
tion of recipient age. Heart–lung and bilateral transplan-
tation are restricted to patients under 55 years of age and
single LTx is restricted to patients under 60 years of age. 
A Council for Lung and Heart–Lung Transplantation
Organized with Related Societies approved 16 pul-
monary diseases and one status (Table 1).3 The indica-
tions for LTx include pulmonary vascular diseases,
parenchyma lung diseases and diffuse pulmonary lesions
due to several systemic diseases. Although survival limita-
tion of candidates has not been clearly decided in Japan,
an estimated survival of less than 2–3 years, as for 
candidates in Western countries, is usually accepted.4 The
transplant window means a recipient who has severe res-
piratory failure but does not have irreversible damage in
other organ functions (Fig. 1). The transplant window must
be considered in the assessment of each patient. Early
registration is strongly recommended in the US because
there is expected to be a wait of more than 600 days
before LTx. The 6 min walk distance is thought to be a
good indicator of total cardiopulmonary function.5 How-
ever, it is difficult to assess the condition of each can-
didate, with a variety of pulmonary disorders, using a
common standard. Therefore, international guidelines for
the selection of LTx candidates based on major indications
were submitted in 1998 (Table 2).6 These guidelines are
very useful and are also acceptable in our country.
Registration for LTx in Japan
Candidates for LTx from BDCD must be registered on the
Japan Organ Transplant Network (JOTNW) waiting list.
Table 1 Indications for lung transplantation in Japan
Primary pulmonary hypertension
Idiopathic pulmonary fibrosis
Chronic emphysema
Bronchiectasis
Sarcoidosis
Lymphangioleiomyomatosis
Eisenmenger’s syndrome
Other type of interstitial pneumonia*
Bronchiolitis obliterans
Pneumoconiosis
Pulmonary eosinophilic granuloma
Diffuse panbronchiolitis
Chronic thromboembolic pulmonary hypertension
Multiple pulmonary arteriovenous fistula
α1-Antitrypsin deficiency emphysema
Cystic fibrosis
Progressive pulmonary disease that are approved by a council†
*Interstitial pneumonia except for idiopathic pulmonary fibrosis.
†The Council for Lung and Heart-Lung Transplantation Organized
with Related Societies in Japan.
Table 2 International guidelines for the selection of lung
transplant candidates
Chronic obstractive lung disease
FEV1 < 25% predicted
PaCO2  55 mmHg
Cor pulmonale
Bronchiectasis, cystic fibrosis
FEV1  30% predicted
PaCO2 > 55 mmHg, PaO2 < 55 mmHg
Increasing numbers of hospitalizations
Rapid fall in FEV1
Massive hemoptysis
Increasing cachexia
Idiopathic pulmonary fibrosis
VC < 60–70% predicted
DLCO/VA < 50–60% predicted
Mandatory early referral (rapid progression)
Pulmonary hypertension
NYHA III–IV (despite optimal treatments, including PGI2
CI  2.0 /min per m2
RAP > 15 mmHg
mPAP > 55 mmHg
Eisenmenger’s syndrome
Severe, progressive symptoms
NYHA III–IV (despite optimal treatments)
FEV1, forced expiratory volume in 1 s; VC, vital capacity;
DLCO/VA, diffusion capacity of carbon monoxide corrected for alveolar
volume; CI, cardiac index; RAP, right atrial pressure; mPAP, mean pul-
monary pressure.
The process of registration requires two different appraisals
by LTx assessment committees, which are an institutional/
regional committee and a nationwide committee (Fig. 2).3
In addition, the validity of LTx for each candidate must be
confirmed ethically by the institutional ethics committee.
Thus, in Japan, it takes 2 or 3 months for the assessment
and the process of registration to be completed. During
this process, informed consent is obtained from candi-
dates and their family.
Analysis of waiting patients for LTx
From August 1998 to March 2001, 51 candidates were
accepted and registered on the waiting list. Only eight
patients (16%) have received lung allografts during this
period and 14 patients (27%) have already died (Fig. 3).
Major causes for LTx candidates are primary pulmonary
hypertension (PPH) in 23 cases (45.1%), idiopathic pul-
monary fibrosis/interstitial pneumonia (IPF/IIP) in eight
cases (15.7%), lymphangioleiomyomatosis (LAM) in
seven cases (13.7%) and bronchiectasis (BE) in six cases
(11.8%). The disease entities in Japan are quite different
from those in Western countries (Fig. 4).2 Juvenile emphy-
sema, cystic fibrosis and α1-antitrypsin-deficient emphy-
sema are major indications in the international registry; in
contrast, there are very few cases with these diseases in
Japan.7,8 All eight patients who received LTx are alive and
doing well; in contrast, the survival of the other patients
who could not have LTx is limited (Fig. 5). These prog-
noses for patients who do not undergo LTx vary according
to primary disease. The prognosis for PPH is best, with a
2 year survival for over 80% of cases. The prognosis for
IPF/IIP is worst and all candidates with IPF/IIP had died
within 1 year if they could not receive LTx (Fig. 5).
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Fig. 1 Process of registration on waiting list for lung transplantation with the Japan Organ Transplant Network (JOTNW). During
this process, informed consent is obtained at least twice from patients and their families.
Lung transplantation from BDCD
The first LTx from BDCD were performed at Osaka
University and Tohoku University as left and right two
single LTx from the same donor on March 2000.9,10 Six
LTx from BDCD have been performed in Japan (Table 3).
The types of procedure include single LTx in five cases
and bilateral LTx in one case; the primary diseases are
LAM in three cases, IPF/IIP in two cases and PPH in one
case. All patients who have received LTx are alive and
well and several recipients have already returned to an
active life without oxygen therapy.
Brain dead and living donors
It is estimated that approximately 7000 brain deaths
occur every year in Japan;however, only less than 10
cases a year will be available for LTx based on our exper-
ience to date. The donation may be quite limited,
because the JBDA for organ transplantation requires a
written will for a person to donate his/her organs, which is
estimated only 10% of the population have. A donor card
campaign and education about organ transplantation
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Fig. 2 Transplant (Tx) window and 6 min walk distance. In Japan, the transplant window is thought to be more to the right side
than its correct position, as indicated in this figure.
Fig. 3 Proliferation of lung transplant candidates on the
Japan Organ Transplant Network (JOTNW) waiting list (n = 51).
(), number of patients on the waiting list (n = 51); (),
number of deaths (n = 14; 27%); (), number of lung trans-
plants (n = 8; 16%).
are quite necessary to increase the number of donors.
The lung is very susceptible to damage in the process of
drain death and during management with a ventilator.
Lung edema, aspiration and pneumonia disturb the 
utilization of lung allografts. The utilization of BDCD for
LTx is generally lower than for kidney, liver and heart 
allografts. The average BDCD utilization for LTx is 
only 10–20%.11 Utilization of lungs in the US was 13%
according to the United Network for Organ Sharing
(UNOS) 1998 report (http://www.unos.org; Fig. 6).
Because organ shortages are serious in Western coun-
tries, the criteria for lung donors have been relaxed to
expand donor pools.4,12–14 At present, the upper age limit
has been extended to 65 years. Unilateral chest shadow
on chest X-ray films, a small amount of purulent airway
secretion and detection of bacteria from airway secretion
of donors are no longer contraindications for LTx. These
are called marginal donors. It was reported that number
of lung donors increased 1.4–2.0-fold after utilization of
marginal donors.13,15–17 We have attempted to use mar-
ginal donors aggressively and could use lung grafts in
five of 13 BDCD (36%) (Table 4).
Living-donor lobar transplantation
Living-donor lobar LTx (LDLTx) was introduced as an
alternative method to expand donor pools. The first LDLTx
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Fig. 4 Survival possibility for lung transplant candidates. (a) Survival with or without lung transplantation (n = 51). The survival of
eight patients who received lung transplantation (Tx) was significantly better than that of the remaining 43 patients who did not
receive lung Tx. (b) Survival without lung Tx of major indications (n = 37). PPH, primary pulmonary hypertension; IPF/IIP, idiopathic
pulmonary fibrosis/interstitial pneumonia; LAM, lymphangioleiomyomatosis; BE, bronchiectasis. Survivals vary according to primary
diseases. The 1 year survival for patients with PPH is over 80%; in contrast, all patients with IPF/IIP without lung transplantation died
within 1 year.
Fig. 5 Composition of pulmonary diseases of lung transplant
candidates in Japan (n = 51). DPB, diffuse panbronchiolitis;
BO, bronchiolitis obliterans; BE, bronchiectasis; PPH, primary
pulmonary hypertension; IPF/IIP, idiopathic pulmonary fibro-
sis/interstitial pneumonia; LAM, lymphangioleiomyomatosis.
applied to an infant used one lobe in 1990.18 Thereafter,
double-lobar transplantation from two living was donors
developed and applied to adult patients.19–21 Because
BDCD is not frequent in Japan, LDLTx is chosen as
another option more frequently in Japan than in the US.
In Japan, after the first LDLTx at Okayama University in
1998,22 eight LDLTx have been performed (Table 5). All
LDLTx were double-lobar transplantation from two living
donors and each donor provided a right or left lower
lobe. Primary diseases of the recipients were BE in two
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Table 3 Lung transplantation from brain-dead cadaver donors in Japan
Case no. Date of Tx Donor Recipient Method of LTx Transplant center
1 29/3/2000 Female,* 20s (Tokyo) Female, 30s, LAM Single LTx (right) Tohoku University
2 29/3/2000 Female,* 20s (Tokyo) Female, 40s, IPF/IIP Single LTx (left) Osaka University
3 8/7/2000 Female, 10s (Fukuoka) Female, 40s, LAM Single LTx (left) Tohoku University
4 8/1/2001 Male, 30s (Tokyo) Male, 40s, IPF/IIP Single LTx (right) Tohoku University
5 21/1/2001 Female, 50s (Kanagawa) Female, 30s, LAM Single LTX (left) Osaka University
6 19/3/2001 Male, 20s (Nara) Male, 20s, PPH Bilateral LTx Osaka University
*Case 1 and 2 were transplanted with a right or left lung graft from the same donor.
Tx, transplant; LTx, lung transplant; LAM, lymphangioleiomyomatosis; IPF/IIP, idiopathic pulmonary fibrosis/interstitial pneumonia, PPH, primary
pulmonary hypertension.
Table 4 Organ transplantation from brain-dead cadaver donors in Japan (n = 13) from October 1997 to April 2001
Donated organ No. utilized donors No. transplanted No. transplantations
organs
Kidney 12 23 23
Liver 11 11 12*
Pancreas 3 3 3
Heart 10 10 10
Lung 5 7 6
*Including two cases of split liver transplantation from the same donor.
Table 5 Lung transplantation from living donors in Japan
Case no. Date of Tx Donor Recipient Transplant center
1 28/10/1998 Mother, 40s Female, 20s, BE Okayaka University
Sister, 20s
2 12/1/2000 Brother, 20s Male, 30s, BE Osaka University
Brother, 20s
3 10/5/2000 Mother, 50s Female, 20s, BO* Okayaka University
Brother, 20s
4 25/7/2000 Father, 50s Female, 20s, IPF/IIP Tohoku University
Mother, 50s
5 18/10/2000 Mother, 50s Female, 20s, LAM Okayaka University
Brother, 20s
6 5/1/2001 Father, 50s Female, 10s, PPH Okayaka University
Mother, 50s
7 28/2/2001 Husband, 30s Female, 30s, IPF/IIP Okayaka University
Sister, 30s
8 27/3/2001 Father, 30s Male, 10s, BO** Okayaka University
Mother, 30s
*Post-bone marrow transplantation (Tx); **due to Steven–Johnson syndrome.
LAM, lymphangioleiomyomatosis; IPF/IIP, idiopathic pulmonary fibrosis/interestitial pneumonia; PPH, primary pulmonary hypertension; 
BO, bronchiolitis obliteraus.
cases, bronchiolitis obliterans in two cases, IPF/IIP in two
cases, LAM in one case and PPH in one case. All patients
who received LDLTx are alive and well. Living-donor
organ transplants have been mainstreams in renal and
liver transplantation in Japan because of a severe donor
shortage. The same trend may develop for LTx. However,
the cumulative number of LDLTx is only less than hun-
dreds in the world; at present, LDLTx is still a developing
and experimental treatment for terminal respiratory disor-
ders and the advantages and disadvantages of LDLTx
should be carefully considered.21,23–26 The benefits of
LDLTx are: (i) scheduled and well-prepared operations;
(ii) excellent donor assessment and condition; (iii) short
graft ischemic time; and (iv) mild rejection compared with
cadaver transplantation because of minor HLA mismatch
between blood relatives. In contrast, the disadvantages
and risks of LDLTx are: (i) surgical risks for two living
donors; (ii) 10–20% loss of donor lung function; (iii) diffi-
culty of the LDLTx operation compared with cadaver LTx;
and (iv) a limit to the lung volume that can be donated.
Universal guidelines for donors for LDLTx have not yet
been established.25,26 We have restricted living donors 
to family members, from 19 to 60 years of age, with 
compatible blood types. Transplant lung volume is the
most important restrictive factor. Using our criteria, 
the estimated volume of donor lobes must be more 
than 50% predicted vital capacity of the recipient.
PROSPECTS FOR LTX AND PROBLEMS TO BE
SOLVED
The beginning of LTx in Japan is more than 10 years
behind the US; nevertheless, early excellent results were
obtained, possibly because initial transplant centers were
restricted to four well-prepared and advanced hospitals.
After a successful beginning, acceptable intermediate
results will be most important to establish LTx as a clinical
option for end-stage lung diseases in the Japanese com-
munity. In order to achieve this, the establishment of a
management system of far-distant transplant patients is
essential. Prompt and precise communication between
recipients, local hospitals and transplant centers can be
maintained with telephone, fax and especially with the
internet. Early detection and measures against chronic
rejection are keys for long survival and for maintaining
good allograft function. In addition, Japanese health
insurance shall cover LTx and immunosuppressive drugs
as early as possible. Many patients cannot be considered
as candidates for economic reasons. Lung transplanta-
tion for children is also a subject to be considered,
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Fig. 6 Organ utilities of brain dead cadaver donors for transplantation in the US (from the United Network for Organ Sharing
(UNOS) and Organ Procurement and Transplantation Network (OPTN) 1998 report; http://www.unos.org). (), number of donors
of each organ; (), number of organs utilized.
because, at present, only living related LTx is a possible
transplant option for children in Japan. Utilization of
BDCD under 15 years of age, split lobar transplantation
from adult lung allograft and down-sizing LTx must be
considered in LTx for children and infants.27–29
Finally, expansion of the donor source is the most
important and urgent problem. Clinical lung preservation
longer than 8 h and clinical utilization of lung allografts
from cardiac arrest donors will be acceptable goals in
the near future. Both have been already established in
animal experiments and clinical trials are underway.30
Thereafter, xenotransplantation and/or artificial lungs will
be appear on the horizon as the next goals to be solved in
the 21st century.
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